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Background: The study was conducted to assess the prevalence of
genetic variation in warfarin metabolism and its effect on main-
tenance dose in patients requiring oral anti-coagulation.
Methods: Among the patients finally selected for the study,
further evaluation done as per the following protocol: Genetic
testing for warfarin metabolism was done by collecting 3ml of
blood in EDTA vials for CYP2C9 polymorphisms. Simultaneously
patients were started on warfarin (7.5 mg) and then its dose
adjusted with frequent INR initially till it achieves therapeutic
levels. According to genetic composition patients will be catego-
rized into three groups’ namely extensive metaboliser, interme-
diate metaboliser& low metaboliser. Analysis of time required to
achieve target INR and stable maintenance dose done among the
above mentioned groups and analysis of bleeding or thrombo-
embolic episodes, if any, done among the above mentioned
groups.
Results: In this study 70% patients were normal metabolizers for
warfarin, 16.7% patients were intermediate metabolizers and only
13.3% patients were poor metabolizers. In this study it was seen
that mean maintenance dose of warfarin to achieve therapeutic
INR in patients with normal metabolism was 6 mg and mean time
required to achieve therapeutic INR in patients with normal
metabolism was 5.19 days, whereas mean maintenance dose to
achieve therapeutic INR in patients with intermediatemetabolism
was 4.7 mg and mean time required to achieve therapeutic INR in
patients with intermediate metabolism was 8.8 days. It was seen
that in patients with poor metabolismmeanmaintenance dose to
achieve therapeutic INR was 2.75mg and the mean time required
to achieve therapeutic INR was 15.5 days.
Conclusion: This study shows that patient with genetic mutation
in CYP2C9 required low maintenance dose of warfarin and
increased time to achieve therapeutic INR depending on the de-
gree of mutation.
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predict the outcomes of PTMC better than the total
Wilkins score? e An analysis from a tertiary care
centre
P.K. Dash, B. Barooah, Prayaag Kini, R. Vrayani
Sri Sathya Sai Institute of Higher Medical Sciences, Whitefield,
Bangalore, India
Introduction: Though the Wilkins’ score is the most commonly
used scoring system for predicting success of balloon mitral val-
votomy, it has important practical shortcomings such as inability
to include unicommissural v/s bicommissural involvement , in-
fluence of rhythm, involvement of underlying myocardium due to
fibrosis, no account of underlying PAH, degree of interatrial septal
bulge etc.This study was conducted to compare the influence of
individual parameters that comprise Wilkins’ score to know
whether one or more parameters of the score were more predic-
tive for PTMC outcomes than the composite score put together.
Methods: 100 patients of rheumatic mitral valve stenosis in sinus
rhythm who underwent balloon mitral valvotomy were studied
for outcomes of the procedure.The composite Wilkins’ score was
calculated for each patient as per protocol pre-PTMC, and the
outcomes of the procedure were studied comparing the total
Wilkins’ score and the individual parameters that comprised the
Wilkins’ score( M/S/T/C).Patients in AF were excluded because AF
itself is a well-documented negative predictor of successful PTMC
outcomes. Successful PTMC was defined as gain in MVA to more
than twice the pre PTMC area, or absolute more than 1.5 sq cm,
with no more than one grade increase in MR and no complica-
tions. Post PTMC MR was classified as either Commissural or
Leaflet tear and quantified as per standard ASE criteria, and post-
PTMC pericardial tamponade was also recorded.
Results: Over a 15-month data among the serially recruited 100
patients (M¼47:F¼53),the average Wilkins’ score was 9.72+/-
1.3.The average post ePTMC MVA was 1.7±0.5 cmsq.24 patients
Table- Baseline, 1 & 3-month parameters.
Ivabradine Atenolol
Baseline 1 Month 3 Month p-value
Baseline vs.
3 month
Baseline 1 Month 3 Month p-value
Baseline vs.
3 month
Resting HR
(Bpm)
92.5 ±11.5 67.1± 6.2 65.5 ±6.2 <0.001 91.9 ±8.3 69.4 ±6.5 67.1 ±4.2 <0.001
Max. HR
(Bpm)
162.3± 10.1 128.7 ±8.5 127.4± 8.5 <0.001 163.1 ±10.3 132.8 ±8.2 129.3 ±7.7 <0.001
METS 6.4 ±1.7 8 ±1.1 8.3± 0.9 <0.001 6.3± 1.6 7.6 ±1 7.7± 1 <0.001
TED (min) 5.3± 1.7 6.6 ±1.2 6.8± 1.1 <0.001 5.1 ±1.8 5.8± 1.4 6 ±1.4 <0.001
TOS (min) 4.4± 1.6 5.5± 1.1 5.7 ±1 <0.001 4.3 ±1.7 4.6 ±1.3 4.8± 1.2 <0.001
MDG
(mm of Hg)
11.9± 6 8.1± 3.4 7.3± 3 <0.001 12.1± 6.2 9± 4.2 8.4 ±3.6 <0.001
EDG
(mm of Hg)
11.5± 7.2 8.6± 4.8 7.7 ±3.8 <0.001 10.9 ±7.2 8.6± 4.2 7.7 ±3.8 <0.001
RVSP
(mm of Hg)
39.7 ±22.4 31.2 ±13.6 27.2± 10.1 0.01 39.6 ±21.8 37.2± 21.8 35.3± 17.6 0.06
MVA (cm2) 1.2± 0.3 1.19± 0.3 1.17 ±0.3 0.86 1.2± 0.2 1.17 ±0.2 1.15± 0.2 0.56
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